These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 20501524)
1. MALT lymphoma of the lacrimal gland in the context of systemic lupus erythematosus: complete remission after treatment with rituximab. Tektonidou MG Lupus; 2010 Sep; 19(10):1243-5. PubMed ID: 20501524 [TBL] [Abstract][Full Text] [Related]
2. Lacrimal gland extranodal marginal zone B-cell lymphoma of MALT-type. Kao SC; Kau HC; Tsai CC; Tsay SH; Yang CF; Wu JS; Hsu WM Am J Ophthalmol; 2007 Feb; 143(2):311-316. PubMed ID: 17184716 [TBL] [Abstract][Full Text] [Related]
3. Lacrimal gland orbital lobe cysts associated with MALT lymphoma and primary Sjögren's syndrome. Cassidy DT; McKelvie P; Harris GJ; Rose GE; McNab AA Orbit; 2005 Dec; 24(4):257-63. PubMed ID: 16354635 [TBL] [Abstract][Full Text] [Related]
8. Systemic lupus erythematosus in a patient with primary MALT lymphoma of the larynx. Gonzàlez N; Xicoy B; Olivé A; Jové J; Ribera JM; Feliu E Ear Nose Throat J; 2009 Aug; 88(8):E4-5. PubMed ID: 19688705 [TBL] [Abstract][Full Text] [Related]
9. Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma. Pijpe J; van Imhoff GW; Vissink A; van der Wal JE; Kluin PM; Spijkervet FK; Kallenberg CG; Bootsma H Ann Rheum Dis; 2005 Jun; 64(6):958-60. PubMed ID: 15576414 [TBL] [Abstract][Full Text] [Related]
10. [Rituximab therapy for systemic manifestations and MALT lymphomas of the parotid gland in Sjögren's disease: preliminary data]. Logvinenko OA; Vasil'ev VI; Sedyshev SKh; Safonova TN; Rodionova EB; Kokosadze NV; Aleksandrova EN; Cherkasova MV; Radenska-Lopovok SG; Nasonov EL Ter Arkh; 2012; 84(12):88-96. PubMed ID: 23479998 [TBL] [Abstract][Full Text] [Related]
11. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type. Salar A; Domingo-Domenech E; Estany C; Canales MA; Gallardo F; Servitje O; Fraile G; Montalbán C Cancer; 2009 Nov; 115(22):5210-7. PubMed ID: 19672998 [TBL] [Abstract][Full Text] [Related]
12. Oral chlorambucil for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue of the orbit. Ben Simon GJ; Cheung N; McKelvie P; Fox R; McNab AA Ophthalmology; 2006 Jul; 113(7):1209-13. PubMed ID: 16647129 [TBL] [Abstract][Full Text] [Related]
13. Primary radiation therapy in patients with localized orbital marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT Lymphoma). Son SH; Choi BO; Kim GW; Yang SW; Hong YS; Choi IB; Kim YS Int J Radiat Oncol Biol Phys; 2010 May; 77(1):86-91. PubMed ID: 19632068 [TBL] [Abstract][Full Text] [Related]
14. Intralesional Rituximab for the Treatment of Recurrent Ocular Adnexal Lymphoma. Demirci H; Kauh CY; Rajaii F; Elner VM Ophthalmic Plast Reconstr Surg; 2017; 33(3S Suppl 1):S70-S71. PubMed ID: 26950471 [TBL] [Abstract][Full Text] [Related]
15. Use of rituximab for periocular and intraocular mucosa-associated lymphoid tissue lymphoma. Shetty RK; Adams BH; Tun HW; Runyan BR; Menke DM; Broderick DF Ocul Immunol Inflamm; 2010 Apr; 18(2):110-2. PubMed ID: 20370339 [TBL] [Abstract][Full Text] [Related]